Acrux Ltd (ACR) – Company Profile and SWOT Analysis

Acrux Ltd (ACR) – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

Acrux Ltd (Acrux) is a speciality pharmaceutical company. It specializes in developing and commercializing generic topical prescription products. The company’s product portfolio includes Dapsone 5% gel, approved by the FDA for acne vulgaris and launched in the US under a license with TruPharma, and Lidocaine and Prilocaine 2.5%/2.5% licensed to Padagis. The company also developed Lenzetto, a transdermal estradiol spray for menopause-related hot flushes, licensed to Gedeon Richter in Europe, and Evamist, another estradiol spray licensed to Padagis. Acrux’s pipeline features Efinaconazole 10% solution, Dapsone 7.5% gel, Acyclovir 5% cream, and Nitroglycerin 0.4% ointment. Acrux is headquartered in West Melbourne, Victoria, Australia.

Scope

• Detailed information on Acrux Ltd required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Acrux Ltd in the form of a SWOT analysis

• An in-depth view of the business model of Acrux Ltd including a breakdown and examination of key business segments

• News about Acrux Ltd, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Gain understanding of Acrux Ltd and the factors that influence its strategies.

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Acrux Ltd as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Acrux Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Ajanta Pharma Ltd

Glenmark Pharmaceuticals Ltd

Teva Pharmaceutical Industries Ltd

Synthesis Med Chem Pty Ltd

Pfizer Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Acrux Ltd - Key Facts

Acrux Ltd - Key Employees

Acrux Ltd - Key Employee Biographies

Acrux Ltd - Major Products and Services

Acrux Ltd - History

Acrux Ltd - Company Statement

Acrux Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Acrux Ltd - Business Description

Other Break-up: Other Revenue

Performance

Other Break-up: Revenue from Product Agreements

Performance

Geographical Segment: Australia

Performance

Geographical Segment: United States

Performance

R&D Overview

Acrux Ltd - Corporate Strategy

Acrux Ltd - SWOT Analysis

SWOT Analysis - Overview

Acrux Ltd - Strengths

Acrux Ltd - Weaknesses

Acrux Ltd - Opportunities

Acrux Ltd - Threats

Acrux Ltd - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026

Acrux Ltd, Recent Deals Summary

Section 5 – Company’s Recent Developments

Dec 12, 2025: Divestment of Prilocaine

2.5% and Lidocaine

2.5%, Cream

Nov 13, 2025: Acrux Receives $0.4 Million Advance on FY26 R&D Tax Incentive

Nov 04, 2025: Acrux Announces Appendix 4C and Financial Results for the Quarter Ended September 2025

Jul 30, 2025: Acrux Announces Appendix 4C and Financial Results for the Quarter Ended June 2025

Jul 03, 2025: Acrux Receives Second Advance From Radium Capital

May 07, 2025: Acrux : Chief Executive Officer and Managing Director Appointment

Apr 30, 2025: Acrux Announces Appendix 4C and Financial Results for the Quarter Ended March 2025

Apr 03, 2025: Acrux Receives $1.73 Million Advance on FY25 R&D Tax Incentive

Feb 07, 2025: Acrux CEO announces plan to retire

Jan 30, 2025: Acrux : Quarterly Activities Report and Appendix 4C – December Quarter 2024

Section 6 – Appendix

Methodology

Ratio Definitions

About MarketLine

Contact Us

Disclaimer

List of Tables

List of Tables

Acrux Ltd, Key Facts

Acrux Ltd, Key Employees

Acrux Ltd, Key Employee Biographies

Acrux Ltd, Major Products and Services

Acrux Ltd, History

Acrux Ltd, Subsidiaries

Acrux Ltd, Key Competitors

Acrux Ltd, Ratios based on current share price

Acrux Ltd, Annual Ratios

Acrux Ltd, Annual Ratios (Cont…1)

Acrux Ltd, Annual Ratios (Cont…2)

Acrux Ltd, Interim Ratios

Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026

Acrux Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Acrux Ltd, Performance Chart (2021 – 2025)

Acrux Ltd, Ratio Charts

Acrux Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026

Acrux Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

    Pricing

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports